Maestro

Moon Surgical (private, with offices in Paris and San Carlos, California; led by CEO Anne Osdoit, with Intuitive Surgical co-founder Fred Moll as board chair and backers including Sofinnova Partners and NVIDIA's venture arm NVentures) makes Maestro, a laparoscopic surgical-assistant and collaboration robot that holds and positions instruments and the endoscope alongside the surgeon rather than acting as a full master-slave teleoperation console, targeting the large pool of soft-tissue procedures unserved by teleoperated robots. The commercial Maestro received FDA 510(k) clearance under K240598 on June 5, 2024, and the company reports more than 1,100 patients treated across the US and Europe, on roughly $90 million-plus in funding. A notable AI distinction in this cohort: Maestro's ScoPilot is a genuinely shipped, FDA-cleared AI feature for intraoperative scope control, powered by NVIDIA Holoscan and cleared with a Predetermined Change Control Plan, rather than a mere demonstration, which sets Maestro apart from the teleoperation-only platforms here. A pathway correction worth recording: Maestro went the 510(k) route under K240598, not the de novo route sometimes assumed, with the contemporaneous de novo authorizations belonging to different companies such as Virtual Incision and MMI. The registry records Maestro at commercial maturity, an early-commercial collaborative-assist robot past its gating event, while noting that its CE mark status, exact installed-system count, and the more-than-1,100-patients figure are not independently verified.

Maestro is listed at $300,000 to $800,000 on the DEPLOY registry. This is an analyst estimate, not an official price.

Yes. Maestro is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.

Not verified as fully autonomous. Maestro's capabilities on the DEPLOY registry are recorded as teleoperated-assisted, demonstrated-only, or vendor claims (Assists surgery), not independently confirmed to run without a human in the loop.

Maestro is made by Moon Surgical, based in San Carlos, California, USA, founded in 2020.

1 verified deployment of Maestro is on the DEPLOY registry, including at Jacksonville.

Maestro is in pilot deployments with named customers and is not yet broadly for sale.

Maestro has 3 regulatory records on the DEPLOY registry: FDA 510(k) clearance, cleared; FDA 510(k) clearance (K240598), cleared; FDA 510(k) clearance (K240598), cleared. See the Regulatory filings section for each agency source.

On the DEPLOY registry, comparable surgical robots to Maestro include da Vinci (and Ion), Edge Multi-Port Surgical Robot, Edison Histotripsy System, Stryker Mako SmartRobotics.

Maestro and da Vinci (and Ion) (Intuitive Surgical · 15 deployments) are both surgical robots on the DEPLOY registry. Maestro has 1 verified deployment on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.

On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Maestro ranks in roughly the top 48% of surgical models tracked by the registry.

Maestro is at the pilot stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Pilot stage means at least one named-customer trial deployment is verified.

Maestro has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.